Welcome to Drug and Alcohol Treatment
| ||
Dopamine Drug Treatment Dose Article
This is a selection made from among articles on Dopamine Drug Treatment Dose. For a permanent link to this article, or to bookmark it for future reading, click here.
from:
Alcohol Abuse and Alcohol Rehab
By Jonathan Huttner
Alcoholism and Alcohol Rehab Alcoholism is a serious disease and the problem is growing. The National Council On Alcoholism And Drug Dependence statistics reveal that approximately 18 million Americans suffer from alcohol abuse. Each year more than 100,000 Americans die from alcohol related deaths and alcohol is a factor in nearly half of all traffic fatalities. Over half of the men and women in the United States report that one or more of their family members have an alcohol abuse problem.
According to the National Institute On Alcohol Abuse And Alcoholism, alcoholism is a disease that has four main components:
. Craving - An overwhelming need to drink
. Loss of Control - An inability to put the drink down
. Physical Dependence - After a period of heavy drinking withdrawal symptoms occur
such as nausea, shaking, and anxiety
. Tolerance - Needing greater amounts of alcohol to obtain a "high" Alcohol Abuse Complications
The complications to the body from alcohol abuse may include damage to the brain and central nervous system, liver disorders, gastrointestinal problems, cardiovascular problems, diabetes complications, sexual and menstrual dysfunction, birth defects, neurological complications and increased risk of cancer.
There is no cure for alcoholism. Even if an alcoholic has long-term sobriety, he or she remains susceptible to relapse. To guard against a relapse, an alcoholic must avoid drinking alcohol. There is treatment for the disease and a chance to build a healthier lifestyle. Addiction treatment generally depends on the severity of alcoholism and alcohol abuse. It may include the following:
. Detox and withdrawal-a process of safely removing alcohol from the body
lasting from a period of days to weeks.
. Assessment and treatment for medical problems related to physical damage from the
disease
. Drug addiction treatment-some medications are used to reduce the craving for alcohol or to
produce severe physical reactions such as nausea and vomiting if one drinks while on
the medication. Drug treatment does not cure alcoholism nor will they remove the
desire to drink.
. Individual/Group Counseling-There are effective methods of counseling that help the
alcoholic to identify feelings that trigger the urge to drink and alternatives to manage
those feelings.
Checking in to a drug rehab or alcohol rehab program is an excellent method of treatment for alcohol abuse. There are many types of addiction treatment or alcohol treatment programs.Some offer alcohol detox and inpatient addiction treatment and others offer shorter-term residencies, sober living or outpatient counseling. When researching drug rehabs, ask what addiction treatment services they offer.If you are looking for an alcohol treatment program, alcohol rehab program or drug rehab program you can call 1-800-511-9225, a national alcohol treatment program helpline.
Jonathan Huttner is a principal with lakeview HealthySystems, an alcohol rehab and addiction treatment program, with a specialty in dual diagnosis.
Article Source: http://EzineArticles.com/?expert=Jonathan_Huttner
http://EzineArticles.com/?Alcohol-Abuse-and-Alcohol-Rehab&id=389352
Dopamine Drug Treatment Dose Specific links
Dopamine Drug Treatment Dose News
Dopamine Beta Hydroxylase Deficiency, Rare Disorder, Causes Severe Head Rushes
When Megan Kenny was five years old, she began to exhibit a strange and troubling symptom: Every time she stood up for more than two minutes, she collapsed.
Read more...Latuda® (lurasidone HCl) Label Updated With Expanded Dosing Range Providing Added Flexibility for the Treatment of ...
Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved an expanded dose range for LATUDA in the treatment of adult patients with schizophrenia.
Read more...Domperidone Poses Risk Of Heart Death, U.K. Regulator Says
Domperidone poses risk of heart death, U.K. regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), just announced. Citing epidemiological studies, the agency announced that domperidone may be associated with a small, increased risk of serious ventricular arrhythmia or sudden … Continue reading →
Read more...Press Release
Sunovion Pharmaceuticals Inc. Posted on:05 May 12 Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded dose range for LATUDA in the treatment of adult patients with schizophrenia.
Read more...A Ticket to Ride from AdComm to PDUFA
A Ticket to Ride from AdComm to PDUFA
Read more...Clinical trial participation might help discover a cure for Parkinson's
Clinical trials are central to Parkinson's disease (PD) treatment breakthroughs and, ultimately, a cure.
Read more...Diagnosis like 'winning the lottery'
When Megan Kenny was five years old, she began to exhibit strange and troubling symptoms. "I've seen dead people with higher blood pressure," one nurse told her parents.
Read more...New Study Shows Patients Can Effectively be Switched to Latuda® (lurasidone HCl) from Other Antipsychotic Agents
Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA .
Read more...Phase 3 Study Shows Efficacy is Maintained With lisdexamfetamine dimesylate (LDX) in Children and Adolescents With ...
Nyon, Switzerland (ots/PRNewswire) - Significantly lower proportion of subjects experiencing treatment failure whilst receiving LDX in the randomised withdrawal period, compared to those subjects...
Read more...Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Third Positive Phase III Study for Levomilnacipran in ...
Forest Laboratories, Inc. and Pierre Fabre Medicament today announced additional positive results from a Phase III clinical trial of levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder .
Read more...